Business

October 28, 2013 5:15 PM

Biogen Idec revenue up 32 percent in third quarter

Drugmaker Biogen Idec reported that sales of its new multiple sclerosis drug Tecfidera helped fuel a 32 percent jump in revenue in the third quarter.

Related content

Suggested for you

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos

Raleigh Top Jobs

View All Top Jobs